Alkem Laboratories Ltd Directors Report.

To the Members

Dear Members,

Alkem Laboratories Limited

Your Directors are pleased to present their 47th Annual Report on the business and operations together with the Audited Financial Statements of the Company for the financial year ended 31s* March, 2021. Consolidated performance of the Company and its subsidiaries has been referred to, wherever required.

FINANCIAL PERFORMANCE

(Rs. in million)

Standalone Consolidated
Particulars Year ended 31st March, 2021 Year ended 31st March, 2020 Year ended 31st March, 2021 Year ended 31st March, 2020
Income from Operations 72,196.8 66,770.8 88,650.1 83,443.6
Other Income 1,900.1 959.8 2,332.1 1,042.2
Total Revenue 74,096.9 67,730.6 90,982.2 84,485.8
Profit before Interest, Depreciation and Tax 21,261.6 15,636.3 21,756.0 15,776.1
Less: Interest 429.3 387.1 589.2 650.6
Less: Depreciation 1,989.3 1,868.4 2,745.8 2,527.6
Profit before tax 18,843.0 13,380.8 18,421.0 12,597.9
Less: Provision for Taxation (net) 1,992.2 736.6 2,243.3 1,104.8
Profit after tax and before Non-Controlling Interest 16,850.8 12,644.2 16,177.7 11,493.1
Less: Non-Controlling Interest - - 327.5 222.4
Profit for the year 16,850.8 12,644.2 15,850.2 11,270.7
Other comprehensive income (49.9) (172.8) (343.0) 268.6
Other comprehensive income attributable to Non-Controlling Interest - - 3.4 5.4
Total comprehensive income attributable to owners of the Company 16,800.9 12,471.4 15,510.6 11,544.7
Balance of other equity as of 01.04.2020 62,565.3 54,413.0 61,367.6 54,154.3
Dividend on Equity Shares (3,347.8) (3,587.0) (3,347.8) (3,587.0)
Dividend Distribution Tax - (732.1) - (743.8)
Employee Stock Option exercised - - (3.3) (2.1)
Employee Compensation Expenses - - 1.1 1.5
Balance of other equity as of 31.03.2021 76,018.4 62,565.3 73,528.2 61,367.6

COVID-19

India is currently experiencing a massive second wave of Covid-19 infections. During the unprecedented Covid-19 pandemic situation, the Company has taken a number of drastic measures to ensure safety of workforce. This Covid-19 crisis is having a far-reaching socio-economic impact throughout the world. We are humbled to be part of an industry that directly impacts lives and remain committed to serve our great country and our people during this crisis. During this period of nationwide lockdown, the Company has mobilised its resources and experience to ensure the uninterrupted supply of its medicines and critical drugs in the market. Through this period of global health crisis, the Company will continue to work towards ensuring availability of medicines for treatment of the patients.

Safeguarding the health of our health warriors, who are the major mainstay to continue the fight against this deadly virus, is the most important aspect where support is needed. The Company has been upfront in providing support to these warriors and have supplied them with masks, gloves and PPE kits. Providing these kits helps the Doctors, Medical Staffs, the Police personnel, etc. some preparedness and mental strength, to battle the crisis out in their work places, and helps to instill relationship building between them, the patients and the public. We have also supported in providing food packets and ration kits to the poor families to safeguard them and their families from the impact of hunger and starvation in different parts of the country. The senior management team came together in solidarity, to support the establishment of the Covid-19 testing Laboratories, which was of dire need at that moment of time and has also provided oxygen concentrators and oxygen cylinders in the hospitals of Dhar, Sikkim, Daman and Baddi (H.P) to support our health warriors in treatment of this deadly virus. Further, the physical and emotional wellbeing of employees continues to be a top priority for the Company, with several initiatives to support employees and their families during this pandemic.

OVERVIEW OF FINANCIAL PERFORMANCE

During the financial year ended 31st March, 2021, the Companys total revenue including other income was Rs. 74,096.9 Million on standalone basis as against Rs. 67,730.6 Million achieved in the previous year, registering a growth of 9%.

The export turnover of the Company during the financial year 2020-21 was Rs. 19,039.0 Million as against Rs. 15,917.1 Million achieved in the previous year registering a growth of 19.6%.

During the financial year ended 31s* March, 2021, the Company and its subsidiaries achieved a total revenue including other income of Rs. 90,982.2 Million on consolidated basis, as against a turnover of Rs. 84,485.8 Million achieved in the previous year, registering a growth of 8%.

During the financial year ended 31s* March, 2021, Standalone Profit before interest, depreciation and tax increased by 36% at Rs. 21,261.6 Million as against Rs. 15,636.3 Million in the previous year, whereas Consolidated Profit before interest, depreciation and tax increased by 38% at Rs. 21,756.0 Million as against Rs. 15,776.2 Million in the previous year. As a result, Standalone Profit before tax grew by 41% over the previous year to Rs. 18,843.0 Million and Consolidated Profit before tax was Rs. 18,421.0 Million, which grew by 46% over the previous year.

The Standalone net profit after tax for the financial year ended 31s* March, 2021 increased by 33% to Rs. 16,850.8 Million over the previous year while the Consolidated net profit after tax increased by 41 % over the previous year to Rs. 15,850.2 Million.

DIVIDEND

During the financial year 2020-21, Board of Directors on 05th February, 2021 declared and paid an interim dividend at Rs. 25/- (Rupees Twenty Five only) per equity share of Rs. 2/- (Rupees Two only) each, being 1250% of paid up share capital of the Company. In addition, your Directors are pleased to recommend payment of Rs. 5/- (Rupees Five only) per equity share of Rs. 2/- (Rupees Two only) each as final dividend for the financial year 2020-21, for the approval of the Members at the ensuing Annual General Meeting (AGM) of the Company. If approved, the total dividend (interim and final dividend) for the financial year 2020-21 will be Rs. 30/- (Rupees Thirty only) per equity share of Rs. 2/- (Rupees Two only) each as against the total dividend of Rs. 25/- (Rupees Twenty Five only) per equity share of Rs. 2/- (Rupees Two only) each paid for the previous financial year.

In compliance with the requirement of Regulation 43A of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "SEBI LODR Regulations"), the Company has formulated its Dividend Distribution Policy, which is available on the Companys website at https://www.alkemlabs. com/pdf/policies/977928327Dividend_distribution_policy.pd f

The said Policy is also annexed to this Report as Annexure A.

TRANSFER TO RESERVES

The Company has not transferred any amount to the General Reserve for the financial year 2020-21.

SHARE CAPITAL

The paid up Equity Share Capital of the Company as on 31s* March, 2021 was Rs. 239.1 Million. The Company has neither issued shares with differential rights as to dividend, voting or otherwise nor issued shares to the Employees or Directors of the Company, under any Scheme (including sweat equity shares).

DEPOSITS

The Company has not accepted any deposits from the public/ members during the year under review and accordingly no amount on account of principal or interest on public deposits was outstanding as on 31s* March, 2021.

SUBSIDIARIES

As on 31s* March, 2021, the Company has 23 subsidiaries. The Company does not have any joint venture / associate company(ies) within the meaning of Section 2(6) of The Companies Act, 2013 (hereinafter referred to as "the Act").

During the year under review, while none of the companies ceased to be a subsidiary of the Company, the following companies were added in the list of subsidiaries of the Company:

• S&B Pharma LLC has been incorporated as a step down subsidiary of the Company in USA on 08th April, 2020, and

• On 12th June, 2020, the Company acquired M/s Connect 2 Clinic Private Limited, a Company incorporated under the Companies Act, 2013.

Pursuant to the first proviso to Section 129(3) of the Act and Rule 5 and Rule 8(1) of the Companies (Accounts) Rules, 2014, the salient features of financial statements, performance and financial position of each subsidiary is given in Form AOC-1 as Annexure B to this Report.

The Audited Financial Statements of the subsidiaries are available on the Companys website at https://www.alkemlabs.com/ subsidiary-accounts.php pursuant to Section 136 of the Act.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed report on the Management Discussion and Analysis is provided as a separate section forming part of this Report.

CORPORATE GOVERNANCE

In compliance with Regulation 34 read with Schedule V of the SEBI LODR Regulations, a Report on Corporate Governance for the year under review is provided as a separate section along with a certificate from the Statutory Auditors conforming the Companys compliance with the conditions of Corporate Governance, forming part of this Report.

BUSINESS RESPONSIBILITY REPORT

In compliance with Regulation 34 of SEBI LODR Regulations, the Business Responsibility Report, describing the initiatives taken by the Company from an environmental, social and governance perspective, is provided as a separate section forming part of this Report.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Companys CSR initiatives are as per the Companys CSR Policy. Our CSR program aims to address the immediate and long term needs of the community and focus on where we can make the major impact on marginalized sections of the society. The Companys CSR strategy involves a multi-sectoral inclusive approach to focus on community needs. It strives to improve the well-being of our communities by focusing on education, vocational training, healthcare and sanitation, environmental concerns and rural development. The Company implements these activities directly or through strategic trust-based partnerships with various NGOs. During the financial year 2020-21, the Company has addressed the requirements of local communities in the vicinity of its manufacturing facilities and R&D centers through focused projects in the areas of education, health and hygiene, environment and community development.

During the year under review, your Company has partnered with Tata Memorial Centre for establishment of: (i) an advanced Radiotherapy Facility as a part of the Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur; and (ii) 3 mini cancer units in the following cities of Bihar namely Buxar, Jehanabad and Bhagalpur as part of its CSR activity.

Details about the Companys CSR Policy and initiatives undertaken by the Company during financial year 2020-21 are outlined in the Report on CSR Activities annexed to this Report as Annexure C.

The Policy on CSR is posted on Companys website: https:// www.alkemlabs.com/pdf/policies/csr-policy.pdf

DIRECTORS AND KEY MANAGERIAL PERSONNEL Appointments

There has been no change in the constitution of the Board of Directors and Key Managerial Personnel of the Company during the year under review.

Considering the expiry of term of Dr. Dheeraj Sharma, Independent Director of the Company on 25*h May, 2022, on the recommendation of Nomination & Remuneration Committee, the Board of Directors of the Company pursuant to the provisions of Sections 149 and 152 of the Act, the Articles of Association of the Company and considering the integrity, expertise and experience of Dr. Dheeraj Sharma, has approved his re-appointment as an Independent Director of the Company for a second term of 5 (five) consecutive years w.e.f. 26*h May, 2022 up to 25*h May, 2027, subject to the approval of the Members of the Company.

Resignations/Retirements/Demise/Completion of Tenure

The Company did not receive any resignation of Directors or Key Managerial Personnel during the year under review.

Directors liable to Retirement by Rotation

Mr. Sandeep Singh (DIN: 01277984) and Mr. Mritunjay Kumar Singh (DIN: 00881412) are liable to retire by rotation at the ensuing AGM of the Company pursuant to the provisions of Section 152 of the Act read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of the Company and being eligible they have offered themselves for re-appointment. Appropriate resolutions, as recommended by the Board of Directors for their re-appointment are included in the Notice of AGM for seeking approval of Members.

Particulars in pursuance of Regulation 36 of the SEBI LODR Regulations read with Secretarial Standard - 2 on General Meetings relating to Mr. Sandeep Singh and Mr. Mritunjay Kumar Singh are given in the Notice of AGM.

Key Managerial Personnel

Mr. Sandeep Singh, Managing Director, Mr. Rajesh Dubey, President Finance and Chief Financial Officer and Mr. Manish Narang, President - Legal, Company Secretary and Compliance Officer are the Key Managerial Personnel of the Company as on 31s* March, 2021, in accordance with the provisions of Section 203 of the Act read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Independent Directors

The Independent Directors hold office for a term of 5 (five) years and are not liable to retire by rotation.

Declaration of independence from Independent Directors

The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence as prescribed under the provisions of the Act, read with the Schedules and Rules issued thereunder, as well as clause (b) of sub-regulation (1) of Regulation 16 of the SEBI LODR Regulations (including any statutory modification(s) or re-enactment(s) thereof for the time being in force). In terms of Regulation 25(8) of the SEBI LODR Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

The terms and conditions of appointment of the Independent Directors are posted on Companys website https://www.alkemlabs.com/pdf/policies/Term_of_ appointment-Independent_Directors.pdf

Familiarization Program

In compliance with the requirements of SEBI LODR Regulations, the Company has put in place a framework for Directors Familiarization Programme to familiarize them with their roles, rights and responsibilities as Directors, the working of the Company, nature of the industry in which the Company operates, business model etc. The details of the Familiarization Programme conducted during the financial year under review are explained in the Corporate Governance Report. The same is also available on the Companys website at https://www.alkemlabs.com/ corporate-governance .

Annual Evaluation of Boards Performance

The details of the annual evaluation of the Individual Directors, Board as a whole and all the Committees of the Board etc. have been provided in the Corporate Governance Report, which forms part of this Report.

The Independent Directors, at a separate meeting held on 16*h March, 2021, evaluated performance of Non-Independent Directors, performance of the Board as a whole and performance of the Chairperson of the Company.

The evaluation of the Independent Directors was carried out by the entire Board of Directors without the participation of the respective Independent Director.

The Company follows a policy for selection and appointment of Directors, Senior Management and their remuneration, which is available on the Companys website at https:// www.alkemlabs.com/pdf/policies/1378936118Nomination -and- Remuneration-Policy_modified%2027052016.pdf. The said Policy is annexed to this Report as Annexure D.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

The disclosure pertaining to remuneration and other details as required under Section 197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this Report as Annexure E.

Further a statement showing the names and other particulars of top ten employees in terms of remuneration drawn and of employees drawing remuneration in excess of the limits required under Section 197(12) of the Act read with Rule 5(2) and Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this Report. However, in terms of first proviso to Section 136(1) of the Act, the Annual Report and Annual Financial Statements are being sent by email to the Members and others entitled thereto, excluding the aforesaid information. The said information shall be provided electronically to any Member on a written request to obtain a copy of the same to the Company Secretary.

NUMBER OF MEETINGS OF THE BOARD

The Board of Directors met 5 (Five) times during the financial year 2020-21. The details of the Board Meetings and the attendance of Directors thereat are provided in the Corporate Governance Report, which forms part of this Report.

COMMITTEES OF THE BOARD Audit Committee

As on 31 March, 2021, the Audit Committee comprised of Mr. Ranjal Laxmana Shenoy as Chairman and Mr. Sandeep Singh, Mr. Mritunjay Kumar Singh, Ms. Sudha Ravi, Ms. Sangeeta Singh and Mr. Narendra Kumar Aneja as Members.

Further, the Board of Directors of the Company at its meeting held on 25*h May, 2021, reconstituted with immediate effect the Audit Committee comprising of Mr. Arun Kumar Purwar as Chairman and Mr. Sandeep Singh, Mr. Mritunjay Kumar Singh, Mr. Ranjal Laxmana Shenoy, Ms. Sangeeta Singh and Mr. Narendra Kumar Aneja as Members.

The brief terms of reference of the Audit Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Nomination and Remuneration Committee

As on 31st March, 2021, the Nomination and Remuneration Committee comprised of Mr. Arun Kumar Purwar as Chairman and Mr. Basudeo N. Singh, Ms. Sangeeta Singh and Mr. Ranjal Laxmana Shenoy as Members.

Further, the Board of Directors of the Company at its meeting held on 25*h May, 2021, reconstituted with immediate effect the Nomination and Remuneration Committee comprising of Mr. Ranjal Laxmana Shenoy as Chairman and Mr. Basudeo N. Singh, Ms. Sudha Ravi and Dr. Dheeraj Sharma as Members.

The brief terms of reference of the Nomination and Remuneration Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Corporate Social Responsibility Committee

As on 31s* March, 2021, the Corporate Social Responsibility Committee comprised of Mr. Ranjal Laxmana Shenoy as Chairman and Mr. Dhananjay Kumar Singh, Mr. Mritunjay Kumar Singh, Mr. Arun Kumar Purwar, Mr. Balmiki Prasad Singh as Members.

Further, the Board of Directors of the Company at its meeting held on 25th May, 2021, reconstituted with immediate effect the CSR Committee comprising of Mr. Arun Kumar Purwar as Chairman and Mr. Basudeo N Singh, Mr. Sandeep Singh, Mr. Dhananjay Kumar Singh, Mr. Mritunjay Kumar Singh, Ms. Sangeeta Singh and Mr. Ranjal Laxmana Shenoy as Members.

The brief terms of reference of the Corporate Social Responsibility Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Stakeholders Relationship Committee

As on 31s* March, 2021, the Stakeholders Relationship Committee comprised of Mr. Ranjal Laxmana Shenoy as Chairman and Mr. Dhananjay Kumar Singh and Mr. Mritunjay Kumar Singh as Members. The brief terms of reference of the Stakeholders Relationship Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Risk Management Committee

As on 31s* March, 2021, the Risk Management Committee comprised of Mr. Dhananjay Kumar Singh as Chairman and Mr. Mritunjay Kumar Singh, Mr. Sandeep Singh, Ms. Sudha Ravi, Dr. Dheeraj Sharma and Mr. Narendra Kumar Aneja as Members. The brief terms of reference of the Risk Management Committee and the particulars of meeting held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

RISK MANAGEMENT

The Companys Board of Directors has overall responsibility for the establishment and oversight of the Companys risk management framework. The Company has a Board approved Risk Management Policy. The Board of Directors has constituted a Risk Management Committee which is delegated with the responsibility of overseeing various strategic, operational and financial risks that the organization faces, along with assessment of risks, their management and mitigation procedures. A detailed analysis of the business risks and opportunities is given under Management Discussion and Analysis Report.

DIRECTORS RESPONSIBILITY STATEMENT

To the best of their knowledge and belief, your Directors confirm that:

(a) in the preparation of the annual accounts for the financial year ended 31st March, 2021, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;

(b) they have selected such accounting policies and applied consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31s* March, 2021 and of the profit of the Company for the year ended on that date;

(c) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) they have prepared the annual financial statements on a going concern basis;

(e) they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively; and

(f) they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

SECRETARIAL STANDARDS

The Directors state that applicable Secretarial Standards, i.e. SS-1 relating to Meetings of the Board of Directors and SS-2 relating to General Meetings have been duly followed by the Company.

AUDITORS AND AUDITORS REPORT Statutory Auditor

Pursuant to the provisions of Section 139 of the Act and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), M/s. B S R & Co. LLP (Firm Registration No: 101248W/W-100022), Chartered Accountants, the Statutory Auditors of the Company, were re-appointed by the Shareholders at the Forty-Fifth AGM of the Company held on 27th August, 2019, for another term of 5 (five) years from the conclusion of Forty-Fifth AGM of the Company until the conclusion of the Fiftieth AGM, on such remuneration, inclusive of applicable taxes and reimbursement of travelling and out of pocket expenses incurred in connection with the audit, as recommended by the Audit Committee and as may be mutually agreed between the Board of Directors of the Company and the Statutory Auditors from time to time. The Company has received a certificate from the said Auditors that they are eligible to hold office as the Auditors of the Company for the current year and are not disqualified from being so appointed.

The Auditors Report for financial year ended 31s* March, 2021, does not contain any qualification, reservation or adverse remark.

Cost Auditor

The Company is required to maintain cost records for certain products as specified by the Central Government under sub-section (1) of Section 148 of the Act, and accordingly such accounts and records are made and maintained in the prescribed manner.

Pursuant to the provisions of Section 148 of the Act and the Rules made thereunder read with notifications/ circulars issued by the Ministry of Corporate Affairs from time-to-time and as per the recommendation of the Audit Committee, the Board of Directors at its meeting held on 05th June, 2020, had appointed Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318), as the Cost Auditor of the Company for the financial year 2020-21 to conduct the audit of the cost records of the Company. A resolution for ratification of the remuneration payable to the Cost Auditor is included in the Notice of AGM for seeking approval of Members. The Cost Audit Report will be filed within the period stipulated under the Act.

Secretarial Auditor

Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. Manish Ghia & Associates, Practicing Company Secretaries, (Membership No. F6252, COP No. 3531) to conduct the Secretarial Audit of the Company for the financial year 2020-21. The Secretarial Audit Report is annexed to this Report as Annexure F. The said Report does not contain any qualification, reservation or adverse remark.

ANNUAL RETURN

The Annual Return of the Company in prescribed Form MGT-7 is available on the website of the Company at https:// www.alkemlabs.com/annual-returns.php

RELATED PARTY TRANSACTIONS

All the Related Party Transactions entered into during financial year 2020-21 by the Company, were at arms length basis and in compliance with the applicable provisions of the Act and the SEBI LODR Regulations and are in conformity with the Companys Policy on Related Party Transactions.

The disclosure of material related party transactions entered into by the Company during the financial year 2020-21, as required under Section 134(3)(h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014 in Form AOC-2

is annexed to this Report as Annexure G. The Related Party Transactions Policy as approved by the Board is uploaded on the Companys website at https://www.alkemlabs.com/ pdf/policies/84051713915915Policy_on_Related_Party_ Transactions.pdf

PARTICULARS OF LOANS/GUARANTEES GIVEN AND INVESTMENTS MADE AND SECURITIES PROVIDED

The particulars of loans, guarantees, investments and securities provided covered under the provisions of Section 186 of the Act have been disclosed in the notes to the financial statements forming part of the Annual Report.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

Pursuant to the provisions of Section 177(9) of the Act, the Board of Directors of the Company has framed the Vigil Mechanism / Whistle Blower Policy for Directors and Employees of the Company. Under the said Policy, provisions have been made to safeguard persons who use this mechanism from victimization. The Policy also provides access to the Chairperson of the Audit Committee under certain circumstances. The Whistle Blower Policy is uploaded on the website of the Company at https://www.alkemlabs.com/pdf/policies/961507913Whistle_ Blower_Policy.pdf

PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

The Company has adopted a policy in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder.

Internal Complaints Committees have been set up at the head office of the Company as well as at all the Companys plants and R&D Centers to redress complaints received on sexual harassment. During the financial year 2020-21, the Company had not received any complaints of sexual harassment.

DISCLOSURES UNDER THE ACT Change in Nature of Business, if any:

During the financial year 2020-21, there was no change in the nature of business of the Company.

Material Changes and Commitments affecting the financial position of the Company:

There are no material changes and commitments, which have occurred between the end of the financial year and the date of the Report which have affected the financial position of the Company.

Significant and Material Orders:

The Company has not received any significant or material orders passed by any regulatory authority, court or tribunal which shall impact the going concern status and Companys operations in future.

Reporting of Frauds by Auditors:

During the year under review, there were no frauds reported by Auditors under Section 143(12) of the Act.

Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made by the Company under the Insolvency and Bankruptcy Code and accordingly the requirement of disclosing the following details are not applicable to the Company:

(i) the details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year alongwith their status as at the end of the financial year; and

(ii) the details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

DETAILS ON INTERNAL FINANCIAL CONTROLS RELATED TO FINANCIAL STATEMENTS

The Company has designed and implemented a process driven framework for Internal Financial Controls (IFC) as mandated under the Act. The Companys policies, guidelines and procedures provide for adequate checks and balances and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the financial year under review, Internal Auditors of the Company with the external audit consultants have reviewed the effectiveness and efficiency of these systems and procedures. As per the said assessment, Board is of the view that IFC were adequate and effective during the financial year.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134(3)(m) of the Act and the Rules framed thereunder is annexed herewith as Annexure H to this Report.

ACKNOWLEDGEMENT

Your Directors would like to express sincere gratitude to all valuable stakeholders of the Company viz., the Central and State Government Departments, Organizations, Agencies, our customers, shareholders, dealers, vendors, banks, medical fraternity, patients and other business associates for their excellent support and co-operation extended by them during the financial year under review.

The Board ofDirectors also places on record its appreciation for the significant contribution made by the employees of the Company through their dedication, hard work and unstinted commitment.

For and on behalf of the Board
Alkem Laboratories Limited
Basudeo N. Singh
Place: Mumbai Executive Chairman
Date: 25*h May, 2021 DIN: 00760310